Cancers and rare genetic disorders are among the diseases that this Oxford University spin-out is targeting with what it claims is an entirely new form of therapeutics. It uses the body’s natural vesicular delivery system, known as exosomes, to deliver drugs directly into patients’ brains. Evox is led by chief executive Dr Antonin de Fougerolles, 53; and its technology, which uses molecular engineering and other techniques, is already being evaluated by German pharmaceutical giant Boehringer Ingelheim. After receiving seed funding of £10m from Oxford Sciences Innovation in 2016, it raised a further £35m in September from investors including Redmile Group and Google’s venture capital arm, GV.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.